2c:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/1bqb83_yclja0.js","/_next/static/immutable/chunks/1on664om2hmh1.js","/_next/static/immutable/chunks/30t4sjq-27eg7.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2d:T8080,

Summary Table

Feature	Details
Risk Factors	Genetic predisposition (family/personal history of atopy: asthma, allergic rhinitis, atopic dermatitis, urticaria, food allergy); low birth weight or prematurity; in-utero and early-life tobacco smoke exposure; exposure to furred animals; early respiratory infections (age 0-12 months); indoor/outdoor pollution (cigarette smoke, cooking fumes, renovation volatiles, factory/burning/wildfire emissions)
Etiology	Chronic airway inflammation driven by Th2-dominant immune response (IL-4, IL-5, IL-13) combined with autonomic nervous system imbalance (reduced sympathetic tone, increased parasympathetic tone) leading to bronchospasm; gene-environment interaction (ADAM33, ORMDL3 genes + environmental inducers/enhancers/triggers)
Patient Presentation	Recurrent episodes of cough, wheezing, dyspnea, or chest tightness; worse at night or early morning (nocturnal/variability); triggered by allergens, exercise, cold air, smoke, viral infections, or strong laughter/crying; reversible spontaneously or with bronchodilators
Classic Physical Exam	May be entirely normal between episodes; during exacerbation: tachypnea, decreased SpO2, chest retractions, bilateral expiratory wheezing; in severe attacks: silent chest; in severe persistent asthma: barrel chest; atopic stigmata: Dennie Morgan lines, allergic shiners, nasal crease, allergic salute, geographic tongue
Key Diagnostic Results	Spirometry: $FEV_1 < 80%$ predicted and/or $FEV_1/FVC < 0.90$; bronchodilator reversibility test: $FEV_1$ increase >12% post-SABA; PEF variability >13% over two weeks; no gold standard test exists; diagnosis is predominantly clinical
Management	Acute: inhaled SABA (salbutamol) + systemic corticosteroids (prednisone 1-2 mg/kg/day, max 40 mg, for 3-5 days); add ipratropium bromide if SABA alone fails. Long-term: inhaled corticosteroids (ICS) as controller (first-line), LTRA as alternative; step-up to ICS-LABA or MART (ICS-formoterol) for persistent moderate-severe; step-down after 3 months of full control
Keywords	"Episodic wheezing," "nocturnal cough," "reversible airway obstruction," "Th2 inflammation," "EVTAR/ENTAR," "bronchodilator response," "atopic history," "step-up/step-down," "MART," "silent chest"

1. Pathophysiology

Pediatric asthma is a heterogeneous, chronic inflammatory disease of the airways that manifests as reversible airflow obstruction and bronchial hyperresponsiveness. Understanding the mechanism begins with the interplay between two foundational processes: chronic airway inflammation and autonomic nervous system imbalance.

The inflammatory cascade begins when a genetically predisposed child (carrying susceptibility genes such as ADAM33 or ORMDL3) encounters environmental inducers like ozone exposure or respiratory viral infections (rhinovirus, RSV, influenza), which sensitize the immune system toward a Th2-dominant response. Once sensitized, subsequent exposure to enhancers such as indoor allergens (house dust mites, mold) drives the immune system into a state of chronic bronchial inflammation. The key cytokines involved are IL-4, IL-5, and IL-13, produced by Th2 lymphocytes. This Th2 dominance is partly enabled by a reduction in regulatory T-cells (Treg) that normally suppress Th2 activity. The result is eosinophilic infiltration, mast cell degranulation releasing histamine, leukotrienes, and prostaglandins, and progressive mucosal edema with mucus hypersecretion.

The autonomic imbalance occurs simultaneously, though its exact mechanism remains incompletely mapped. The normal sympathetic nervous system promotes bronchodilation through beta-2 adrenergic receptor activation. In asthma, sympathetic tone is reduced while parasympathetic (cholinergic) tone is increased, causing smooth muscle spasm and bronchospasm. This concept is directly connected to why the two pillars of asthma therapy exist: anti-inflammatory agents (corticosteroids) to address chronic inflammation, and bronchodilators (beta-2 agonists, anticholinergics) to correct the autonomic imbalance.

Once the airway enters a state of hyperresponsiveness, it has two components: hypersensitivity (the threshold for triggering a response is lowered, so minimal stimuli can provoke symptoms) and hyperreactivity (the response is far more exaggerated than normal). In this primed state, when trigger factors such as cigarette smoke, dust, cold air, or exercise are encountered, a dual response emerges: acute inflammation flares on top of the chronic process, and parasympathetic tone surges further. The combined effect produces airway narrowing through mucosal edema, mucus plugging, and bronchospasm, explaining the triad of cough, wheezing, and dyspnea.

Over time, persistent inflammation leads to airway remodeling: proliferation of airway smooth muscle, subepithelial fibrosis, increased vascularity and angiogenesis, and mucous gland hyperplasia. In severe cases, remodeling causes irreversible airflow limitation. This is why early initiation of anti-inflammatory therapy (ICS) can improve respiratory function and why delayed treatment worsens long-term outcomes.

The hallmark clinical characteristics of asthma (best remembered by the mnemonic EVTAR or ENTAR: Episodicity, Variability/Nocturnal worsening, Trigger-dependence, Atopy/Allergy, Reversibility) are each a direct consequence of these pathophysiological processes. Episodicity reflects the fluctuating nature of the inflammation. Nocturnal worsening reflects circadian changes in autonomic tone and cortisol. Trigger-dependence reflects the hyperresponsive airway. Reversibility reflects that bronchospasm and acute inflammation can be resolved pharmacologically, at least before remodeling becomes fixed.

2. Classification and Clinical Manifestation

By Frequency

Severity	Criteria
Intermittent	Episodes of asthma symptoms once per month or less
Mild Persistent	Episodes 2 or more times per month, but not more than once per week
Moderate Persistent	Episodes more than once per week, but not daily
Severe Persistent	Episodes almost every day

By Severity of Exacerbation

Parameter	Mild-Moderate	Severe	Life-Threatening (Impending Respiratory Arrest)
Consciousness	Not agitated	Agitated	Criteria of severe attack PLUS lethargy
Speech	Full sentences	Words only	Criteria of severe attack PLUS inaudible breath sounds
Respiratory rate	Increased	Increased
Retractions	Minimal	Obvious
SpO2 (room air)	92-95%	<92%

Important rule: If even one criterion falls in a more severe category, the patient is classified and treated at that higher severity level.

By Degree of Control

The degree of asthma control is assessed retrospectively based on the child's condition over the previous four weeks. Four criteria are evaluated:

Daytime asthma symptoms occurring more than twice per week
Nighttime awakening due to asthma
Use of reliever medication more than twice per week
Activity limitation caused by asthma symptoms

The degree of control is classified as:

Fully Controlled: The child meets none of the four criteria. In other words, over the past four weeks:
Partly Controlled: The child meets one to two of the four criteria listed above. This indicates suboptimal control and should prompt the clinician to reassess adherence, inhaler technique, trigger exposure, and comorbidities before considering a step-up in therapy.
Uncontrolled: The child meets three to four of the four criteria. This classification signals a clear need to step up the long-term management regimen after verifying modifiable factors such as incorrect inhaler technique, poor adherence, persistent allergen exposure, or untreated comorbidities.

3. Diagnostic Workup

Test	Role	Key Finding Supporting Asthma
Clinical history (EVTAR/ENTAR)	Best initial approach; cornerstone of diagnosis	Episodic cough/wheeze, nocturnal worsening, triggers, atopy, reversibility; minimum 2 of 5 characteristics
Spirometry ($FEV_1$, $FEV_1/FVC$)	Recommended objective test for airway obstruction	$FEV_1 < 80%$ predicted or $FEV_1/FVC < 0.90$
Bronchodilator reversibility test	Proves reversible obstruction	$FEV_1$ increase >12% post-SABA (spirometry) or PEF increase >20% (PFM)
PEF variability (Peak Flow Meter)	Alternative when spirometry unavailable	Diurnal PEF variability >13% measured over 2 weeks
Bronchial provocation test	Proves hyperresponsiveness	20% fall in $FEV_1$; NOT recommended in children (risk of severe attack)
FeNO, sputum eosinophils	Markers of eosinophilic inflammation	Not recommended as routine diagnostic tests in children
Skin prick test / total IgE / eosinophils	Demonstrate atopy	Not recommended for routine diagnosis; atopy supports but does not confirm asthma
Chest X-ray	Rule out alternative diagnoses	Not routinely recommended; only if another diagnosis is suspected
Empiric SABA trial (3-5 days)	When spirometry/PFM unavailable	Clinical improvement with SABA supports diagnosis; add steroid if no initial response

The diagnostic workup for pediatric asthma begins with a thorough clinical history, which remains the single most important diagnostic step because there is no gold standard test. The physician asks about the pattern of symptoms (cough, wheeze, dyspnea, chest tightness) and specifically screens for the EVTAR/ENTAR characteristics. Finding at least two of the five characteristics (episodicity, variability/nocturnal, trigger, atopy, reversibility) strongly supports the clinical diagnosis.

Physical examination is often normal between episodes. During an attack, findings include tachypnea, wheezing on auscultation, retractions, and decreased oxygen saturation. Signs of atopy (Dennie Morgan lines, allergic shiners, nasal crease, geographic tongue) add supportive evidence.

When available, spirometry is the recommended objective test. It measures $FEV_1$ and $FVC$ to quantify airflow obstruction. A low $FEV_1$ (<80% predicted) or a reduced $FEV_1/FVC$ ratio (<0.90) suggests obstruction. However, a normal result in an asymptomatic child with intermittent asthma does not rule out the diagnosis.

The bronchodilator reversibility test is performed by giving inhaled SABA and repeating spirometry. An increase in $FEV_1$ of more than 12% confirms reversible obstruction characteristic of asthma. Using a Peak Flow Meter (PFM), the threshold is a PEF increase of more than 20%.

If neither spirometer nor PFM is available, the guideline recommends an empiric therapeutic trial: give inhaled SABA for 3-5 days and observe clinical response. If symptoms improve, asthma is the working diagnosis. If there is no response to SABA, a short course of oral steroids (3-5 days) can be added. Persistent failure to respond should prompt investigation for alternative diagnoses.

Critically, tests for atopy (skin prick testing, serum IgE, blood eosinophils) are not recommended as routine diagnostic tools. Atopy increases the probability of asthma but is neither necessary nor sufficient for the diagnosis. Chest X-ray is similarly not routinely indicated and is reserved for cases where TB, foreign body aspiration, or congenital anomalies are suspected.

4. Management and Treatment

Acute Attack Management

Severity	Setting	Treatment
Mild-Moderate	Home	Inhaled SABA via nebulizer (up to 2 doses) or pMDI+spacer (up to 2 rounds of 4 puffs each, 15-30 min apart); if no improvement, go to facility
Mild-Moderate	Primary care / ER	Inhaled SABA (up to 3 doses q20 min in 1 hour); add ipratropium bromide if no response to SABA alone; systemic corticosteroid oral 1-2 mg/kg/day (max 40 mg) for 3-5 days
Severe	Hospital	Oxygen (target SpO2 >94%); SABA + ipratropium bromide q20 min; IV methylprednisolone 1-2 mg/kg/day (max 60 mg/day); high-dose ICS nebulization (budesonide 0.5-1 mg q20 min, total up to 1.5-3 mg); if refractory: IV aminophylline (loading 6-8 mg/kg over 30 min, then 0.5-1 mg/kg/hr) and/or IV MgSO4 (40-50 mg/kg over 60 min, max 1500 mg)
Impending respiratory arrest	ICU	All of the above; prepare for intubation

Long-Term Controller Therapy (Age 6-11 Years)

Classification	First-Line Controller	Reliever	Alternative Controller
Intermittent (Step 1)	None; give low-dose ICS with each SABA use	SABA	Low-dose ICS daily + SABA prn
Mild Persistent (Step 2)	Low-dose ICS daily	SABA	LTRA (montelukast) + SABA prn
Moderate Persistent (Step 3)	Low-dose ICS-LABA or medium-dose ICS; OR very-low-dose ICS-formoterol (MART)	SABA (or formoterol in MART)	Low-dose ICS + LTRA + SABA prn
Severe Persistent (Step 4)	Medium-dose ICS-LABA; OR low-dose ICS-formoterol (MART)	SABA (or formoterol in MART)	Refer to pediatric pulmonologist

Long-Term Controller Therapy (Age 12-18 Years)

Frequency Classification	First-Line (Preferred)	Alternative
Intermittent (Step 1)	Low-dose ICS-formoterol as needed	No controller; SABA + low-dose ICS with each SABA use
Mild Persistent (Step 2)	Low-dose ICS-formoterol as needed	Low-dose ICS daily + SABA prn; OR LTRA + SABA prn
Moderate Persistent (Step 3)	Low-dose ICS-formoterol as MART (controller + reliever)	Low-dose ICS-LABA + SABA prn; OR medium-dose ICS + SABA prn
Severe Persistent (Step 4)	Medium-dose ICS-formoterol as MART	Medium-to-high dose ICS-LABA + SABA prn

Acute Attack: The first priority in any asthma exacerbation is to assess the severity (using the classification table above) and to identify risk factors for asthma-related death (history of intubation/ventilator use, ER visit or hospitalization within the past year, current or recent systemic steroid use, SABA overuse equivalent to >1 canister/month, poor adherence, psychiatric or psychosocial comorbidity, food allergy, or comorbid pneumonia/diabetes/arrhythmia).

For a mild-moderate attack, the standard first step is inhaled SABA, either via nebulizer (salbutamol 2.5 mg/dose) or pMDI with spacer (2-4 puffs, each puff followed by 5-10 breaths through the spacer). This can be repeated every 20 minutes up to three times within one hour. If there is no adequate response to SABA alone, add ipratropium bromide. Systemic corticosteroid (prednisone or prednisolone 1-2 mg/kg/day, max 40 mg orally) is given for 3-5 days without tapering.

For a severe attack, the child should receive oxygen (target SpO2 >94%), combined SABA + ipratropium bromide via nebulizer, IV corticosteroid (methylprednisolone 1-2 mg/kg/day, max 60 mg/day), and high-dose inhaled corticosteroid via nebulizer (budesonide 0.5-1 mg per dose, repeatable up to a total of 1.5-3 mg). If there is no response, IV aminophylline (loading dose 6-8 mg/kg over 30 minutes, maintenance 0.5-1 mg/kg/hour; target serum level 10-20 mcg/mL) and/or IV MgSO4 (40-50 mg/kg over 60 minutes, max 1500 mg single dose) are considered.

For impending respiratory arrest (lethargy, inaudible breath sounds), the child is transferred to ICU and intubation is prepared. A child with dehydration and metabolic acidosis may develop tachyphylaxis to SABA; in that case, give SABA only once and prioritize correcting the dehydration and acidosis first.

Long-Term Controller Therapy: The approach is a personalized, control-based stepwise strategy. The initial step is determined by the frequency classification. Follow-up visits occur every 2-4 weeks initially, then every 1-2 months once stable.

Key principles:

Step-up if asthma is not fully controlled after 6-8 weeks of treatment, but only after confirming correct inhaler technique, adequate adherence, allergen avoidance, and addressing comorbidities.
Step-down if asthma has been fully controlled for at least 3 months and spirometry is stable. Reduce by only one step at a time. Overly rapid step-down increases the risk of severe exacerbation.
A child with intermittent asthma who has one or more risk factors for exacerbation should be managed as mild persistent (step 2).
After a severe or life-threatening attack, the long-term step should be raised one level higher than what the frequency classification alone would dictate.

MART (Maintenance and Reliever Therapy): ICS-formoterol is used as both the daily controller and the as-needed reliever. Formoterol is a LABA with rapid onset, making it suitable for both roles. MART has been shown to reduce exacerbation risk compared to separate ICS controller with SABA reliever, and is available for children 6-11 years (step 3-4) and 12-18 years (step 1-4). Maximum daily formoterol dose is 54 mcg/day.

Contraindications and cautions: Oral corticosteroids given long-term as a controller are not recommended due to side effects (hypertension, growth suppression, osteoporosis). LTRA (montelukast) is offered when families prefer oral medication, when ICS is unavailable, or when ICS is contraindicated. Parents must be educated about potential montelukast side effects including sleep disturbance and behavioral changes. For children aged <4 years, ICS-LABA combination does not yet have sufficient safety data and is not globally recommended.

Montelukast (LTRA) dose: 4 mg for ages 2-5, 5 mg for ages 6-14, 10 mg for ages 15 and above, given once daily at bedtime.

5. Differential Diagnosis and Distractors

DifferentiaL	Why It Looks Similar	Key Discriminator
Bronchiolitis	Wheezing in a young child with respiratory distress	Typically first episode of wheezing, age <2 years, preceded by viral URI prodrome; asthma is recurrent/episodic and typically >2 years
Foreign body aspiration	Acute-onset wheezing and respiratory distress	Unilateral wheezing (not bilateral), sudden onset with history of choking or aspiration event
Chesty child (noisy breathing in obese infant)	Wheezing in an infant, may have atopic history	Infant with obesity who is otherwise happy/well (no respiratory distress), no other symptoms; the noise is not true bronchospasm
GERD	Chronic cough, sometimes nocturnal	Cough accompanied by recurrent vomiting, failure to thrive, Sandifer posturing; no wheezing or episodic pattern
Pertussis	Prolonged/paroxysmal cough	Paroxysmal "whooping" cough with post-tussive vomiting, subconjunctival hemorrhage; no wheezing
Rhinosinusitis / Chronic Upper Airway Cough Syndrome	Chronic cough, may worsen at night	Morning sneezing, post-nasal drip (PND), nasal congestion, sinus tenderness, throat clearing; no wheezing, no episodic pattern
Tuberculosis	Chronic cough, especially in endemic areas	Prolonged cough >2 weeks, contact history, weight loss/failure to thrive, night sweats; chest X-ray may show hilar lymphadenopathy or infiltrate
Laryngomalacia / Tracheomalacia	Noisy breathing or stridor in infants	Inspiratory stridor (not expiratory wheeze), worsens with feeding or crying, typically presents in early infancy; no response to bronchodilators
Cough variant asthma (CVA)	Chronic cough without wheezing	This is actually a form of asthma; characterized by cough with asthma-like features (episodic, triggered by cold air/exercise, reversible) but without audible wheezing; responds to bronchodilator trial
Congenital heart disease	Dyspnea, sometimes wheezing ("cardiac wheeze")	Murmur on auscultation, cyanosis, signs of heart failure (hepatomegaly, peripheral edema), failure to thrive; does not respond to SABA

6. Traps and High-Yield Pearls

The single most common trap on this topic is the assumption that "all that wheezes is asthma." The guideline dedicates an entire chapter to diagnostic errors, and test-writers love to exploit this. A vignette describing unilateral wheezing should immediately redirect you to foreign body aspiration, not asthma. A first-time wheezer under age 2 with a viral prodrome is bronchiolitis until proven otherwise.

Equally important is the reverse trap: underdiagnosis of cough variant asthma (CVA). A child who presents with chronic, episodic, nocturnal cough triggered by cold air or exercise but without audible wheezing can still have asthma. If the vignette describes cough with EVTAR characteristics but no wheeze, and the answer choices include "CVA" or "empiric bronchodilator trial," that is the intended answer. Asthma does not require spirometry for diagnosis, and the absence of a spirometry result in the vignette should not dissuade you from choosing asthma.

Another classic gotcha involves treatment errors. Test-writers will present a child with persistent asthma who is using SABA daily as the sole therapy. The correct next step is to add a controller (ICS), not to continue or increase SABA. Overreliance on SABA without controller therapy leads to tachyphylaxis, beta-2 receptor downregulation, increased inflammation, and higher risk of severe exacerbation. Similarly, using low-dose ICS to treat an acute attack is incorrect; during an exacerbation, ICS must be given at high doses if used at all, and systemic corticosteroids remain the standard.

Watch for vignettes that include antihistamine use during an acute asthma attack. First-generation antihistamines thicken mucus and worsen obstruction. This is a commonly tested management error.

The question of "silent chest" is a high-yield pearl: a child with severe asthma who suddenly has no audible wheezing is not improving. The absence of wheezing in the context of severe respiratory distress indicates such severe obstruction that airflow is insufficient to generate sound. This is an ominous sign indicating impending respiratory arrest.

Finally, remember the step-down rule: asthma must be fully controlled for at least 3 months before reducing therapy, and you can only step down one level at a time. Step-up, by contrast, can occur after 6-8 weeks of failed control, but only after verifying inhaler technique, adherence, trigger avoidance, and comorbidity management. The core competency being tested here is the ability to integrate classification, control assessment, and stepwise management into a logical, evidence-based sequence of decisions.

1d:["$","$L2c",null,{"article":{"id":"2c4bd58d-2116-4b9c-95ab-6fc8a4723258","title":"Asma Bronkiale Anak","content":"$2d","category":"Respirologi","created_at":"2026-09-05T22:27:35.958038+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]